Alto Neuroscience (ANRO) Interest Expenses (2023 - 2026)
Alto Neuroscience (ANRO) posted Interest Expenses of $545000.0 for Q1 2026, up 327.08% sequentially from -$240000.0 in Q4 2025, and down 72.75% YoY from $2.0 million in Q1 2025.
Alto Neuroscience (ANRO) Interest Expenses (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported Interest Expenses for 4 years, with the latest figure at $545000.0 in Q1 2026.
- Quarterly Interest Expenses fell 72.75% year-over-year to $545000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $653000.0 (down 67.35% YoY) and the FY2025 annual result came in at $52.1 million, up 39.42% from the prior year.
- Interest Expenses climbed to $545000.0 in Q1 2026 per ANRO's latest filing, from -$240000.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $1.8 billion in Q3 2025 and troughed at -$240000.0 in Q4 2025.
- A 4-year average of $169.7 million and a median of $400000.0 in 2023 frame the typical range for Interest Expenses.
- The widest YoY moves for Interest Expenses: up 527120.63% in 2025, down 23900.0% in 2025.
- Over 4 years, Interest Expenses stood at -$102000.0 in 2023, then jumped by 99.02% to -$1000.0 in 2024, then tumbled by 23900.0% to -$240000.0 in 2025, then soared by 327.08% to $545000.0 in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $545000.0, -$240000.0, and $1.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - | 130.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 130.24 Mn |
| Jun 30, 2026 | 130.24 Mn |
| Mar 31, 2026 | 545,000.00 |
| Mar 31, 2026 | 545,000.00 |
| Dec 31, 2025 | -240,000.00 |
| Dec 31, 2025 | -240,000.00 |
| Sep 30, 2025 | 1.84 Bn |
| Sep 30, 2025 | 1.84 Bn |
| Jun 30, 2025 | 362.00 Mn |
| Jun 30, 2025 | 362.00 Mn |
| Mar 31, 2025 | 2.00 Mn |
| Mar 31, 2025 | 2.00 Mn |
| Dec 31, 2024 | -1,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Sep 30, 2024 | 349,000.00 |
| Sep 30, 2024 | 349,000.00 |
| Jun 30, 2024 | 400,000.00 |
| Jun 30, 2024 | 400,000.00 |
| Mar 31, 2024 | 346,000.00 |
| Mar 31, 2024 | 346,000.00 |